Gomez-Veiga, F <br/><br/>
Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.  [electronic resource] 

 -  Actas urologicas espanolas  May 2013 
 - 292-304 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1699-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.acuro.2012.09.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Antibodies, Monoclonal, Humanized--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Bone Density Conservation Agents--pharmacology<br/>Bone Neoplasms--complications<br/>Clinical Trials, Phase III as Topic<br/>Denosumab<br/>Diphosphonates--pharmacology<br/>Double-Blind Method<br/>Forecasting<br/>Fractures, Spontaneous--etiology<br/>Humans<br/>Imidazoles--pharmacology<br/>Male<br/>Models, Biological<br/>Molecular Targeted Therapy<br/>Multicenter Studies as Topic<br/>Neoplasm Proteins--antagonists & inhibitors<br/>Practice Guidelines as Topic<br/>Prostatic Neoplasms--pathology<br/>Quality of Life<br/>RANK Ligand--antagonists & inhibitors<br/>Randomized Controlled Trials as Topic<br/>Receptor Activator of Nuclear Factor-kappa B--physiology<br/>Zoledronic Acid